Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Study Title
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
Teva Identifier
C38072/3084
ClinicalTrials.gov Identifier
NCT01508936
Study Status
Completed
Trial Condition(s)
Eosinophilic Asthma
Interventions
Drug: Reslizumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 65 Years
Trial Duration
02/01/2012 - 08/01/2013
Phase
Phase 3

Study Type

Interventional